Almirall wins positive CHMP opinion to expand Klisyri treatment area for actinic keratosis
Almirall has received a positive CHMP opinion recommending an expanded treatment area for Klisyri (tirbanibulin), allowing application to up to 100 cm² of facial or scalp skin in adults with actinic keratosis.
The European Medicines Agency recommendation would increase the approved treatment area fourfold from 25 cm², with European Commission approval expected within approximately 60 days.
The expansion is supported by the phase 3 TirbAKare study, which evaluated tirbanibulin in patients with actinic keratosis across treatment areas of up to 100 cm². The study demonstrated a statistically significant reduction in lesions compared with vehicle, with efficacy and tolerability consistent with the original pivotal trials.
The five-day treatment regimen remains unchanged, potentially offering dermatologists greater flexibility when managing patients with widespread actinic kerosis across sun-damaged skin.
Treating larger fields of sun-damaged skin
Actinic keratosis is a common precancerous skin condition caused by prolonged ultraviolet exposure. Lesions can develop into squamous cell carcinoma, making continued monitoring and treatment important.
Patients frequently present with multiple lesions across larger areas of sun-damaged skin rather than isolated patches. Expanding the treatment field could therefore help dermatologists manage more extensive disease without extending the treatment duration.
Almirall’s chief scientific officer Karl Ziegelbauer said: “Actinic keratosis rarely occurs as isolated lesions, and dermatologists in Europe need effective therapeutic options to treat larger affected skin areas.”
Phase 3 data support expanded application
The TirbAKare study enrolled 280 patients with four to 12 actinic keratosis lesions across areas larger than 25 cm² and up to 100 cm². Participants were randomised in a 2:1 ratio to receive tirbanibulin or vehicle over five days.
The primary endpoint was percentage reduction in lesion count from baseline to week 8. Tirbanibulin demonstrated a statistically significant reduction compared with vehicle, with a safety profile consistent with the original trials.
Patients who did not achieve complete clearance at week 8 could receive a second treatment course under the study protocol. The trial included a 16-week study period followed by 32 weeks of follow-up.
European approval now awaits final decision
The European Commission will now review the CHMP recommendation, with a final decision expected in approximately 60 days. If approved, the expanded indication would apply across EU member states, as well as Iceland, Liechtenstein and Norway.
The US Food and Drug Administration approved an expanded treatment area of up to 100 cm² in June 2024, making the European recommendation a further regulatory step for the established dermatology treatment.




